Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Just two weeks after announcing a development collaboration deal with Onyx Pharmaceuticals on JAK2 inhibitors, Singapore-based S*BIO announced it inked a licensing deal Jan. 21 with San Diego-based Tragara Pharmaceuticals covering its multi-kinase inhibitor SB1317 for leukemia

You may also be interested in...



COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial

Tragara Pharmaceuticals, Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves using a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy.

COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial

Tragara Pharmaceuticals, Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves using a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy.

Singapore's S*BIO Initiates Phase II Trials In Canada; Picks Up New Investor

Singapore-based biotech company S*BIO announced it has initiated Phase II trials of its oral histone deacetylase (HDAC) inhibitor SB939 in prostate cancer

Related Content

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel